TrialThe New England journal of medicine2023
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in
Caicun Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
134 papers cite itlatest 60 shown
this paperpooled ittrialcites it